A Phase 2 interventional study of Doxorubicin and cyclophosphamide (AC) + bevacizumab and Docetaxel (T) + bevacizumab in Breast Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-14.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.
Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 33rd largest by enrollment of the 189 interventional ones that give a count, is one of 19 that started in 2006, is one of 110 in phase 2, and was the 72nd registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 126 · Phase 3 30 · Phase 4 9
First in 1993; this study’s year is marked. 19 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 189 interventional studies. Of the 142 that completed or were terminated, 69 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 197 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
40 studies in Breast Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 40 studies in Breast Neoplasms by Sanofi, this one is the 11th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2006, is one of 21 in phase 2, and was the 11th registered.
Sanofi’s Breast Neoplasms studies by the year they started, since 1994.
4 of the studies testing doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT02897700Shanghai Jiao Tong University School of MedicineA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | 2026-12 |
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 197 studies testing doxorubicin in Breast Neoplasms, from their registry updates:
Among Sanofi’s 40 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different docetaxel-based combination regimens for the adjuvant treatment of participants with node positive or high-risk node negative breast cancer.
In this study, participants were stratified according to HER2 status at the time of enrollment. HER2-negative participants were randomized in a 1:1 ratio to either stratum 1 (AC->T sequential + bevacizumab) or stratum 2 (TAC + bevacizumab). All HER2-positive participants were assigned to stratum 3 (TCH + bevacizumab).
The study included a treatment period of 1 year, followed by a 2 year posttreatment survival follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following information on clinical trials is provided for information purposes only to allow participants and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.
Inclusion Criteria:
High-risk, lymph node-negative participants, (pN0) will be defined as subjects having invasive adenocarcinoma with either a negative sentinel node (pN0[sn]) OR negative lymph node dissection (pN0) disease AND tumor size > 2 cm or tumor size >/= 1 cm with at least one of the following factors:
Hematology evaluation within 2 weeks prior to study entry:
Hepatic function evaluation within 2 weeks prior to study entry:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2-negative participants administered * doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by * docetaxel (T) + bevacizumab for 4 cycles followed by * bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed
Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab · Drug: Docetaxel (T) + bevacizumab · Drug: Bevacizumab maintenance therapy
HER2-negative participants administered * docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by * bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed
Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab · Drug: Bevacizumab maintenance therapy
All HER2-positive participants administered * docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by * bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed
Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab · Drug: Bevacizumab and trastuzumab maintenance therapy
Drug pages: Doxorubicin · Cyclophosphamide · Bevacizumab
For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Also known as: Avastin® (bevacizumab), Adriamycin® (doxorubicin)
Drug pages: Docetaxel · Bevacizumab
For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * docetaxel 100 mg/m\^2 IV * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction
Also known as: Taxotere® (docetaxel), Avastin® (bevacizumab)
Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide · Bevacizumab
For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2 * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Also known as: Taxotere® (docetaxel), Avastin® (bevacizumab)
Drug pages: Docetaxel · Carboplatin · Trastuzumab · Bevacizumab
For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by * trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2) * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Also known as: Taxotere® (docetaxel), Herceptin® (trastuzumab), Avastin® (bevacizumab)
Drug pages: Bevacizumab · Trastuzumab
* bevacizumab 15 mg/kg was infused IV followed by * trastuzumab 6 mg/kg IV Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Also known as: Avastin® (bevacizumab), Herceptin® (trastuzumab)
- bevacizumab 15 mg/kg was infused IV Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.
Also known as: Avastin® (bevacizumab)
Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)
Participants were evaluated for clinical CHF every 3 weeks during chemotherapy, every 3 months while on maintenance therapy, and every 3 months during the 2-year follow-up period. Left ventricular ejection fraction (LVEF) of CHF was assessed by multi-gated acquisition (MUGA) or echocardiogram (ECHO) performed midway through completion of chemotherapy according to a treatment-specific schedule, every 12 weeks during maintenance therapy, and at 6 and 24 months after completion of maintenance therapy. Grade 3-4 CHF were identified through a clinical review of all study collected investigator verbatim and the Medical Dictionary for Regulatory Activities (MedDRA). The preferred terms (PT) cardiac failure congestive, cardiomyopathy, and ejection fraction decreased were associated with CHF.
Time frame: from the first dose of study medication up to the end of follow-up (up to 3 yrs)
Safety - Number of Participants With Adverse Events (AE)
An adverse event was any untoward medical occurrence in a participant of the clinical investigation, regardless of the relationship to study treatment. A serious adverse event (SAE) was an AE that at any dose (including overdose) resulted in death, was life-threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect, and/or was medically important. Treatment-emergent adverse events (TEAE) were defined as AEs that developed or worsened in severity during the on-treatment period.
Time frame: from the administration of the first dose of study medication up to 30 days after the last dose of study medication; events ongoing at the time of discontinuation were monitored in the follow-up period until resolution.
Disease-free Survival (DFS) Rate
DFS was defined as the time from the administration of the first-dose of study medication until recurrence of tumor or death from any cause in the absence of previous documentation of tumor recurrence. DFS rate was the probability of being disease free and alive at a particular time. DFS rates were estimated using Kaplan-Meier Method, and 95% confidence intervals were computed using the method of Kalbfleisch and Prentice. For participants who did have objective recurrence of tumor and who were still on study at the time of an analysis, or who were given antitumor treatment other than the study treatment, or who were removed from study follow-up prior to documentation of the tumor recurrence, DFS was censored at the last date the participant was known to be disease-free.
Time frame: from the administration of the first-dose of study medication up to 12 months, 18 months and 24 months
239 participants were screened in this study. 214 were considered eligible for enrollment and 25 were screen failures. Of the 214 eligible participants, 155 were HER2-negative and 59 were HER2-positive.
| Milestone | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) |
|---|---|---|---|
| Started | 78 | 77 | 59 |
| Treated (safety population) | 78 | 75 | 59 |
| Completed treatment | 38 | 36 | 45 |
| Completed | 44 | 41 | 44 |
| Not completed | 34 | 36 | 15 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 |
| Withdrew: Poor compliance to protocol | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 |
| Withdrew: Death | 1 | 3 | 0 |
| Withdrew: Subject's request | 11 | 13 | 1 |
| Withdrew: Disease progression/relapse | 9 | 6 | 7 |
| Withdrew: Adverse event | 6 | 6 | 3 |
| Withdrew: Moved | 2 | 0 | 0 |
| Withdrew: New cancer | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 0 |
| Withdrew: Second malignancy | 0 | 1 | 0 |
| Withdrew: Patient/physician decision | 0 | 0 | 1 |
Participants were evaluated for clinical CHF every 3 weeks during chemotherapy, every 3 months while on maintenance therapy, and every 3 months during the 2-year follow-up period. Left ventricular ejection fraction (LVEF) of CHF was assessed by multi-gated acquisition (MUGA) or echocardiogram (ECHO) performed midway through completion of chemotherapy according to a treatment-specific schedule, every 12 weeks during maintenance therapy, and at 6 and 24 months after completion of maintenance therapy. Grade 3-4 CHF were identified through a clinical review of all study collected investigator verbatim and the Medical Dictionary for Regulatory Activities (MedDRA). The preferred terms (PT) cardiac failure congestive, cardiomyopathy, and ejection fraction decreased were associated with CHF.
| participants | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) |
|---|---|---|---|
| Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF) | 1 (0.0 to 6.9) | 3 (0.8 to 11.2) | 1 (0.0 to 0.1) |
An adverse event was any untoward medical occurrence in a participant of the clinical investigation, regardless of the relationship to study treatment. A serious adverse event (SAE) was an AE that at any dose (including overdose) resulted in death, was life-threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect, and/or was medically important. Treatment-emergent adverse events (TEAE) were defined as AEs that developed or worsened in severity during the on-treatment period.
| participants | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) |
|---|---|---|---|
| with TEAE | 78 | 75 | 59 |
| with serious TEAE | 23 | 24 | 12 |
| with any TEAE leading to death | 0 | 2 | 0 |
| with any TEAE leading to treatment discontinuation | 21 | 24 | 16 |
| with any Grade 3-4 Serious TEAE | 23 | 24 | 9 |
DFS was defined as the time from the administration of the first-dose of study medication until recurrence of tumor or death from any cause in the absence of previous documentation of tumor recurrence. DFS rate was the probability of being disease free and alive at a particular time. DFS rates were estimated using Kaplan-Meier Method, and 95% confidence intervals were computed using the method of Kalbfleisch and Prentice. For participants who did have objective recurrence of tumor and who were still on study at the time of an analysis, or who were given antitumor treatment other than the study treatment, or who were removed from study follow-up prior to documentation of the tumor recurrence, DFS was censored at the last date the participant was known to be disease-free.
| percentage of participants | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) |
|---|---|---|---|
| DFS rate at 12 months | 93.6 (83.8 to 97.5) | 95.9 (87.8 to 98.7) | 98.2 (87.8 to 99.7) |
| DFS rate at 24 months | 87.1 (75.9 to 93.4) | 94.1 (84.8 to 97.8) | 96.3 (86.0 to 99.1) |
| DFS rate at 36 months | 85.5 (74.0 to 92.2) | 90.4 (79.6 to 95.6) | 90.4 (78.5 to 95.9) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AC->T + Bevacizumab | — | 23/78 (29.5%) | 78/78 (100%) |
| TAC + Bevacizumab | — | 24/75 (32%) | 75/75 (100%) |
| TCH + Bevacizumab | — | 12/59 (20.3%) | 59/59 (100%) |
| Event | AC->T + Bevacizumab | TAC + Bevacizumab | TCH + Bevacizumab |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/78 | 8/75 | 0/59 |
| DehydrationMetabolism and nutrition disorders | 1/78 | 4/75 | 0/59 |
| NeutropeniaBlood and lymphatic system disorders | 1/78 | 3/75 | 0/59 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/78 | 2/75 | 0/59 |
| Cardiac failure congestiveCardiac disorders | 1/78 | 2/75 | 0/59 |
| ColitisGastrointestinal disorders | 0/78 | 2/75 | 0/59 |
| Deep vein thrombosisVascular disorders | 2/78 | 1/75 | 0/59 |
| DiarrhoeaGastrointestinal disorders | 1/78 | 1/75 | 1/59 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/78 | 0/75 | 1/59 |
| Irritable bowel syndromeGastrointestinal disorders | 0/78 | 0/75 | 1/59 |
| Event | AC->T + Bevacizumab | TAC + Bevacizumab | TCH + Bevacizumab |
|---|---|---|---|
| FatigueGeneral disorders | 71/78 | 61/75 | 51/59 |
| NauseaGastrointestinal disorders | 64/78 | 60/75 | 51/59 |
| AlopeciaSkin and subcutaneous tissue disorders | 58/78 | 48/75 | 50/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 51/78 | 37/75 | 32/59 |
| DiarrhoeaGastrointestinal disorders | 39/78 | 48/75 | 38/59 |
| AnaemiaBlood and lymphatic system disorders | 45/78 | 42/75 | 32/59 |
| NeutropeniaBlood and lymphatic system disorders | 41/78 | 41/75 | 8/59 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 36/78 | 32/75 | 32/59 |
| ConstipationGastrointestinal disorders | 40/78 | 29/75 | 30/59 |
| Decreased appetiteMetabolism and nutrition disorders | 39/78 | 25/75 | 22/59 |
| Age Continuous(years) | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) | Total |
|---|---|---|---|---|
| Mean | 53.0 ± 10.45 | 55.1 ± 9.89 | 50.8 ± 9.61 | 53.1 ± 10.12 |
| Sex: Female, Male(Participants) | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) | Total |
|---|---|---|---|---|
| Female | 78 | 75 | 59 | 212 |
| Male | 0 | 0 | 0 | 0 |
| Eastern Cooperative Oncology Group Score (ECOG)(participants) | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) | Total |
|---|---|---|---|---|
| ECOG Score = 0 | 73 | 67 | 55 | 195 |
| ECOG Score = 1 | 5 | 8 | 4 | 17 |
| Electrocardiogram (ECG)(participants) | Stratum 1 (AC->T + Bevacizumab) | Stratum 2 (TAC + Bevacizumab) | Stratum 3 (TCH + Bevacizumab).) | Total |
|---|---|---|---|---|
| Normal | 45 | 53 | 36 | 134 |
| Abnormal | 22 | 19 | 19 | 60 |
| Not done/missing | 11 | 3 | 4 | 18 |
The record gives a start of Aug 2006, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doxorubicin · Cyclophosphamide · Bevacizumab · Docetaxel · Carboplatin · Trastuzumab